GRI Bio, Inc. Common Stock

GRINASDAQUSD
2.16 USD
0.72 (24.90%)🟢LIVE (AS OF 10:44 AM EDT)
🟢Market: OPEN

GRI Bio, Inc. Common Stock (GRI) trades at $2.16 per share. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, GRI appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Sep 4, 2026.

Open?$2.61
High?$2.75
Low?$1.98
Prev. Close?$2.88
Volume?431.7K
Avg. Volume?595.8K
VWAP?$2.38
Rel. Volume?0.72x
Bid / Ask
Bid?$2.16 × 100
Ask?$2.22 × 100
Spread?$0.06
Midpoint?$2.19
Valuation & Ratios
Market Cap?6.3M
Shares Out?2.2M
Float?1.7M
Float %?97.9%
P/E Ratio?N/A
P/B Ratio?0.61
EPS?-$4.42
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Employees
5
Market Cap
6.3M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2023-04-24
Address
2223 AVENIDA DE LA PLAYA
LA JOLLA, CA 92037
Phone: (619) 400-1171
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Neutral(0/3)
Medium-Term (Wave)? Bullish(+3/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
43
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.10Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?7.33%Elevated
Short Interest?127.1K
Days to Cover?1.0
Free Float1.7M
Avg Daily Volume760.5K
Settlement Date2026-08-14
Financial Health
Current Ratio?10.30Strong
Quick Ratio?10.30Strong
Cash Ratio?9.95Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
97
0.61CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
Peers
100
S&P
97
0.5CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-94.0%WEAK
ROA?
S&P
3
-84.9%WEAK
Cash Flow & Enterprise
FCF?$-10418000
Enterprise Value?$-4650989
Fundamentals ratios updated end of day